NCT04866004Completed
Contingency Management for Cannabis Use for Persons With HIV
Feasibility and Impact of 28-days of Monitored Abstinence From Cannabis Use on Symptoms of Distress, Inflammation, and HIV Viral Load
Source: ClinicalTrials.gov · Last updated 4 Sept 2025
Brief summary (registry, in English)
The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 27 Apr 2021
- Start date
- 1 Aug 2021
- Primary completion date
- 31 Jul 2025
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Diseases
- HIV
- NCT number
- NCT04866004
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From 1 Aug 2021 to the primary completion date, 31 Jul 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving treatment for cannabis or other drug use disorder
- Diagnosed or receiving treatment for a current major depressive or anxiety disorder
Other illness
- Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
- Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.
Other
- Positive UTOX screen for opioids
Who the study is looking for
- HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)
- Self-report of cannabis use at least once per week in the 6-month period prior to consent
- Provide a positive urine toxicology (UTOX) screen for cannabis
- Not seeking treatment for cannabis use
- Willing to stop using cannabis for 28 days and attend eight study visits over six weeks.
- Ability and willingness to provide inform consent
- English fluency
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Neurobehavioral Research on Addiction Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| University of Texas Health Science Center at San Antonio Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.